January 14, 2019
FDA’s approval of Cabometyx was based on results from the phase III pivotal trial of Cabometyx for patients with advanced HCC who received prior sorafenib
ALAMEDA, Calif.–(BUSINESS WIRE)–Jan. 14, 2019– Exelixis, Inc. (NASDAQ:EXEL) today announced that the U.S. Food and Drug Administration (FDA) approved CABOMETYX® (cabozantinib) tablets for patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. […]